Sangamo Therapeutics Shows Market Leadership With Jump To 86 RS Rating


Sangamo Therapeutics (SGMO) saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 80 to 86.

X As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.

This exclusive rating from Investor’s Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock’s price movement over the trailing 52 weeks stacks up against all the other stocks in our database.

Decades of market research shows that the best stocks tend to have an 80 or better RS Rating in the early stages of their moves.

See How IBD Helps You Make More Money In Stocks

Sangamo Therapeutics is not currently offering a proper buying opportunity. See if the stock goes on to build a chart pattern that could ignite a new run.

The company showed 0% EPS growth in the latest quarterly report. Revenue rose 269%.

The company holds the No. 194 rank among its peers in the Medical-Biomed/Biotech industry group. Ligand Pharmaceuticals (LGND), Supernus Pharmaceuticals (SUPN) and Enanta Pharmaceuticals (ENTA) are among the top 5 highly rated stocks within the group.


Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Improved Technical Action?

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

2018-05-17 07:40:00

Read more from source here…


Please enter your comment!
Please enter your name here